Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases

Pediatric Pulmonology

Volumn 50, Issue 4, 2015, Pages 410-419

  Braun, Sarah ^a,b   Ferner, Marion ^c   Kronfeld, Kai ^c   Griese, Matthias ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b German Center for Lung Research (DZL)   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

antimalarials; chILD; chloroquine; diffuse parenchymal lung disease; hydroxychloroquine; Plaquenil; Quensyl

Indexed keywords

AMINOGLYCOSIDE; AMIODARONE; CHARCOAL; CHLOROQUINE; CORTICOSTEROID; DIAZEPAM; HYDROXYCHLOROQUINE; QUININE DERIVATIVE; STEROID; ANTIMALARIAL AGENT;

AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD DISEASE; DIARRHEA; DISEASES; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; EMERGENCY TREATMENT; EPILEPSY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEARING DISORDER; HEMATOLOGIC DISEASE; HISTOLOGY; HUMAN; HYPERTRANSAMINASEMIA; INTERSTITIAL LUNG DISEASE; LIVER DISEASE; LOSS OF APPETITE; LUNG DISEASE; MALARIA; METABOLIC DISORDER; MODERATE RENAL IMPAIRMENT; MYASTHENIA GRAVIS; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PHARMACODYNAMICS; PORPHYRIA; PREGNANT WOMAN; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULOPATHY; REVIEW; SEVERE RENAL IMPAIRMENT; SIDE EFFECT; SKIN DEFECT; SYSTEMIC DISEASE; TREATMENT RESPONSE; LUNG DISEASES, INTERSTITIAL; OFF LABEL DRUG USE;

ANTIMALARIALS; CHILD; HUMANS; HYDROXYCHLOROQUINE; LUNG DISEASES, INTERSTITIAL; OFF-LABEL USE;

EID: 84925647049     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23133     Document Type: Review

References (91)

1. Bush A, Anthony G, Barbato A, Cunningham S, Clement A, Epaud R, Gilbert C, Goldbeck L, Kronfeld K, Nicholson AG, et al. ch ILDc. Research in progress: put the orphanage out of business. Thorax 2013; 68: 971-973.
2. Griese M, Haug M, Brasch F, Freihorst A, Lohse P, von Kries R, Zimmermann T, Hartl D,. Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany. Orphanet J Rare Dis 2009; 4: 26.
3. Kurland G, Deterding RR, Hagood JS, Young LR, Brody AS, Castile RG, Dell S, Fan LL, Hamvas A, Hilman BC, Langston C, Nogee LM, Redding GJ, American Thoracic, Society Committee, on Childhood, Interstitial Lung,. An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Res Crit Care Med 2013; 188: 376-394.
4. Clement A, Nathan N, Epaud R, Fauroux B, Corvol H,. Interstitial lung diseases in children. Orphanet J Rare Dis 2010; 5: 22.
5. Lim HS, Im JS, Cho JY, Bae KS, Klein TA, Yeom JS, Kim TS, Choi JS, Jang IJ, Park JW,. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother 2009; 53: 1468-1475.
6. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR,. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumat 2012; 8: 522-533.
7. Dinwiddie R,. Treatment of interstitial lung disease in children. Paediatr Respir Rev 2004; 5: 108-115.
8. Fan LL, Langston C,. Chronic interstitial lung disease in children. Pediatr Pulmonol 1993; 16: 184-196.
9. Weiss JS,. Antimalarial medications in dermatology. A review. Dermatol Clin 1991; 9: 377-385.
10. Isaacson D, Elgart M, Turner ML,. Anti-malarials in dermatology. Int J Dermatol 1982; 21: 379-395.
11. Dubois EL,. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978; 8: 33-51.
12. Tett SE, Cutler DJ, Day RO, Brown KF,. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy- volunteers. Br J Clin Pharmacol 1988; 26: 303-313.
13. Carmichael SJ, Charles B, Tett SE,. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 2003; 25: 671-681.
14. Fachinformation Quensyl®., Sanofi-Aventis Deutschland GmbH 2013.
15. Warhurst DC, Steele JC, Adagu IS, Craig JC, Cullander C,. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother 2003; 52: 188-193.
16. Lee SJ, Silverman E, Bargman JM,. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011; 7: 718-729.
17. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y,. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42: 145-153.
18. Ziegler HK, Unanue ER,. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Nat Acad Sci USA 1982; 79: 175-178.
19. Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L,. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1- alpha) and IL-6 in human monocytes and T cells. J Rheumatol 1993; 20: 803-808.
20. Loffler BM, Bohn E, Hesse B, Kunze H,. Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. Biochim Biophys Acta 1985; 835: 448-455.
21. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ,. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000; 95: 3460-3466.
22. Lesiak A, Narbutt J, Sysa-Jedrzejowska A, Lukamowicz J, McCauliffe DP, Wozniacka A,. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 2010; 19: 683-688.
23. Kyburz D, Brentano F, Gay S,. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006; 2: 458-459.
24. da Silva JC, Mariz HA, da Rocha LF Jr, de Oliveira PS, Dantas AT, Duarte AL, Pitta Ida, Galdino R, Pitta SL,. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics 2013; 68: 766-771.
25. Askling HH, Bruneel F, Burchard G, Castelli F, Chiodini PL, Grobusch MP, Lopez-Velez R, Paul M, Petersen E, Popescu C, Ramharter M, Schlagenhauf P,. European Society for Clinical M, Infectious Diseases Study Group on Clinical P.Management of imported malaria in Europe. Malar J 2012; 11: 328.
26. Arguin PM, Tan KR,. 2014. Malaria. CDC health information for international travel (Yellow Book). Centers for Disease Control and Prevention.
27. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA,. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheumatol Dis 2010; 69: 20-28.
28. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dorner T, Doria A, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheumatol Dis 2012; 71: 1771-1782.
29. Product Monograph Plaquenil®. Sanofi-Aventis Canada Inc 2013.
30. Laaksonen AL, Koskiahde V, Juva K,. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol 1974; 3: 103-108.
31. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L,. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 1986; 314: 1269-1276.
32. Ziering CL, Rabinowitz LG, Esterly NB,. Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 1993; 28: 764-770.
33. Easterbrook M,. Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarcon. Arthritis Rheum 2003; 48: 863-864; author reply.
34. Rasmussen JE,. Antimalarials-are they safe to use in children. Pediatr Dermatol 1983; 1: 89-91.
35. Fox JN, Klapman MH, Rowe L,. Lupus profundus in children: treatment with hydroxychloroquine. J Am Acad Dermatol 1987; 16: 839-844.
36. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF, American Academy of O. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118: 415-422.
37. Position statement: Screening for hydroxychloroquine retinopathy. American College of Rheumatology; 2011.
38. Hydroxychloroquine in Pediatric Rheumatology. The British Society for Paediatric and Adolescent Rheumatology; 2010.
39. Tonnesmann E, Kandolf R, Lewalter T,. Chloroquine cardiomyopathy-a review of the literature. Immunopharmacol Immunotoxicol 2013; 35: 434-442.
40. Chen CY, Wang FL, Lin CC,. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol 2006; 44: 173-175.
41. Smith ER, Klein-Schwartz W,. Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med 2005; 28: 437-443.
42. Mühlendahl K, Chloroquin. Vergiftungen im Kindesalter, 4 edition. Stuttgart: Thieme; 2003. pp 144-145.
43. Costedoat-Chalumeau N, Amoura Z, Aymard G, Le TH Wechsler, Vauthier D, Dermer ME, Darbois Y, Piette JC,. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002; 46: 1123-1124.
44. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DL, Sebbough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff JM, Piette JC,. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48: 3207-3211.
45. Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A,. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 2013; 39: 58-62.
46. Tarfaoui N, Autret-Leca E, Mazjoub S, Cissoko H, Jonville-Bera AP,. Hydroxychloroquine during pregnancy: a review of retinal toxicity in the newborns. Therapie 2013; 68: 43-47.
47. Osadchy A, Ratnapalan T, Koren G,. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 2011; 38: 2504-2508.
48. Treatment of malaria (Guidelines For Clinicians). Centers for disease control and prevention (CDC); 2013.
49. Olsen NJ, Schleich MA, Karp DR,. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum 2013.
50. Aktories K, Förstermann U, Hofmann FB, Starke K,. 2009. Allgemeine und spezielle Pharmakologie und Toxikologie. Munich: Elsevier GmbH.
51. White NJ, Miller KD, Churchill FC, Berry C, Brown J, Williams SB, Greenwood BM,. Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med 1988; 319: 1493-1500.
52. Callen JP,. Dermatomyositis. Lancet 2000; 355: 53-57.
53. Weingartner JS, Zedek DC, Burkhart CN, Morrell DS,. Lupus erythematosus panniculitis in children: report of three cases and review of previously reported cases. Pediatr Dermatol 2012; 29: 169-176.
54. Meurer M, Childhood discoid, lupus erythematosus, antimalarials. Dermatology 2003; 207: 133.
55. Grondin C, Malleson P, Petty RE,. Slow-acting antirheumatic drugs in chronic arthritis of childhood. Semin Arthritis Rheum 1988; 18: 38-47.
56. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:723-731.
57. Rootman DB, Mustard R, Kalia V, Ahmed N,. Perceptions and realities of testing for alcohol and other drugs in trauma patients. J Trauma 2007; 63: 1370-1373.
58. Baughman RP, Lower EE,. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 2007; 25: 334-340.
59. Baltzan M, Mehta S, Kirkham TH, Cosio MG,. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160: 192-197.
60. Tal A, Maor E, Bar-Ziv J, Gorodischer R,. Fatal desquamative interstitial pneumonia in three infants siblings. J Pediatr 1984; 104: 873-876.
61. Leahy F, Pasterkamp H, Tal A,. Desquamative interstitial pneumonia responsive to chloroquine. Clin Pediatr 1985; 24: 230-232.
62. Farrell PM, Gilbert EF, Zimmerman JJ, Warner TF, Saari TN,. Familial lung disease associated with proliferation and desquamation of type II pneumonocytes. Am J Dis Child 1986; 140: 262-266.
63. Buchino JJ, Keenan WJ, Algren JT, Bove KE,. Familial desquamative interstitial pneumonitis occurring in infants. Am J Med Genet Suppl 1987; 3: 285-291.
64. Kerem E, Bentur L, England S, Reisman J, O'Brodovich H, Bryan AC, Levison H,. Sequential pulmonary function measurements during treatment of infantile chronic interstitial pneumonitis. J Pediatr 1990; 116: 61-67.
65. Spencer DA, Price JF,. A case of fibrosing alveolitis in childhood. J R Soc Med 1991; 84: 234-235.
66. Waters KA, Bale P, Isaacs D, Mellis C,. Successful chloroquine therapy in a child with lymphoid interstitial pneumonitis. J Pediatr 1991; 119: 989-991.
67. Schroeder SA, Shannon DC, Mark EJ,. Cellular interstitial pneumonitis in infants. A clinicopathologic study. Chest 1992; 101: 1065-1069.
68. Bush A, Sheppard MN, Warner JO,. Chloroquine in idiopathic pulmonary haemosiderosis. Arch Dis Child 1992; 67: 625-627.
69. Fan LL, Mullen AL, Brugman SM, Inscore SC, Parks DP, White CW,. Clinical spectrum of chronic interstitial lung disease in children. J Pediatr 1992; 121: 867-872.
70. Campos JM, Simonetti JP,. Treatment of lymphoid interstitial pneumonia with chloroquine. J Pediatr 1993; 122: 503.
71. Avital A, Godfrey S, Maayan C, Diamant Y, Springer C,. Chloroquine treatment of interstitial lung disease in children. Pediatr Pulmonol 1994; 18: 356-360.
72. Sharief N, Crawford OF, Dinwiddie R,. Fibrosing alveolitis and desquamative interstitial pneumonitis. Pediatr Pulmonol 1994; 17: 359-365.
73. Balasubramanyan N, Murphy A, O'Sullivan J, O'Connell EJ,. Familial interstitial lung disease in children: response to chloroquine treatment in one sibling with desquamative interstitial pneumonitis. Pediatr Pulmonol 1997; 23: 55-61.
74. Schroten H, Manz S, Kohler H, Wolf U, Brockmann M, Riedel F,. Fatal desquamative interstitial pneumonia associated with proven CMV infection in an 8-month-old boy. Pediatr Pulmonol 1998; 25: 345-347.
75. Boyce JA, Mark EJ, Bramson RT, Shannon DC, Youth B,. A four-month-old girl with chronic cyanosis and diffuse pulmonary infiltrates. Cellular Interstitial pneumonitis. N Engl J Med 1999; 341: 2075-2083.
76. Hacking D, Smyth R, Shaw N, Kokia G, Carty H, Heaf D,. Idiopathic pulmonary fibrosis in infants: good prognosis with conservative management. Arch Dis Child 2000; 83: 152-157.
77. Dinwiddie R, Sharief N, Crawford O,. Idiopathic interstitial pneumonitis in children: a national survey in the United Kingdom and Ireland. Pediatr Pulmonol 2002; 34: 23-29.
78. Nikolaidou P, Charocopos E, Anagnostopoulos G, Lazopoulou D, Kairis M, Lourida A, Tzoumakas K, Tsiligiannis T,. Cellular interstitial pneumonitis in children: response to hydroxychloroquine treatment in two Cases. Pediatr Asthma Allergy Immunol 2003; 16: 45-51.
79. Rosen DM, Waltz DA,. Hydroxychloroquine and surfactant protein C deficiency. N Engl J Med 2005; 352: 207-208.
80. Kim HB, Lee SY, Kim JH, Jang JY, Huh J, Park SJ, Hong SJ,. Familial interstitial lung disease in two young Korean sisters. J Korean Med Sci 2005; 20: 1066-1069.
81. Abou Taam R, Jaubert F, Emond S, Le Bourgeois M, Epaud R, Karila C, Feldmann D, Scheinmann P, de Blic J,. Familial interstitial disease with I73T mutation: a mid- and long-term study. Pediatr Pulmonol 2009; 44: 167-175.
82. Thouvenin G, Abou Taam, Flamein R, Guillot F, Le Bourgeois L, Reix M, Fayon P, Counil M, Depontbriand F, Feldmann U, Pointe D, de Blic HD, Clement J, Epaud A,. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95: 449-454.
83. Jirarattanasopa N, Tantikul C, Vichyanond P, Pacharn P, Visitsunthorn N, Suttinont P, Jirapongsananuruk O,. A combination of intravenous immunoglobulin and pulse methylprednisolone extended survival in pulmonary alveolar proteinosis with chronic interstitial pneumonitis: a case report. Asian Pac J Allergy Immunol 2010; 28: 200-205.
84. Hayes D Jr., Lloyd EA, Fitch JA, Bush A,. ABCA3 transporter deficiency. Am J Respir Crit Care Med 2012; 186: 807.
85. Kitazawa H, Moriya K, Niizuma H, Kawano K, Saito-Nanjo Y, Uchiyama T, Rikiishi T, Sasahara Y, Sakamoto O, Setoguchi Y, Kure S,. Interstitial lung disease in two brothers with novel compound heterozygous ABCA3 mutations. Eur J Pediatr 2013; 172: 953-957.
86. Rabach I, Poli F, Zennaro F, Germani C, Ventura A, Barbi E,. Is treatment with hydroxychloroquine effective in surfactant protein C deficiency. Arch Bronconeumol 2013; 49: 213-215.
87. Hepping N, Griese M, Lohse P, Garbe W, Lange L,. Successful treatment of neonatal respiratory failure caused by a novel surfactant protein C p. Cys121Gly mutation with hydroxychloroquine. J Perinatol 2013; 33: 492-494.
88. Williamson M, Wallis C,. Ten-year follow up of hydroxychloroquine treatment for ABCA3 deficiency. Pediatr Pulmonol 2014; 49: 299-301.
89. Avital A, Hevroni A, Godfrey S, Cohen S, Maayan C, Nusair S, Nogee LM, Springer C,. Natural history of five children with surfactant protein C mutations and interstitial lung disease. Pediatr Pulmonol 2014; 49: 1097-1105.
90. Springer C, Maayan C, Katzir Z, Ariel I, Godfrey S,. Chloroquine treatment in desquamative interstitial pneumonia. Arch Dis Child 1987; 62: 76-77.
91. Arikan-Ayyildiz Z, Caglayan-Sozmen S, Isik S, Deterding R, Dishop MK, Couderc R, Epaud R, Louha M, Uzuner N,. Survival of an infant with homozygous surfactant protein C (SFTPC) mutation. Pediatr Pulmonol 2014; 49: E112-E115.